Nuvalent
meet the significant experience in drug discovery development and company building board of directors scientific advisors independent hack bain capital life sciences flare therapeutics management anna protopapas independent james porter professor of chemistry chemical biology independent wheeler management head scientific advisor professor of chemistry chemical biology ross clinical advisor university of colorado clinical advisor memorial sloan cancer center translational research advisor mass general cancer center pasi clinical advisor cancer institute nancy kohl translational research advisor independent consultant leadership team james porter chief executive officer chief financial officer miller chief legal officer chief development turner chief medical officer officer ruth clinical operations josh chemistry benjamin lane technical operations lin corporate strategy portfolio management human resources henry drug discovery injection i i translational development business development strategy bets aga beta | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
7 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
February 2024
meet the significant experience in drug discovery development and company building board of directors scientific advisors independent hack bain capital life sciences flare therapeutics management anna protopapas independent james porter professor of chemistry chemical biology independent wheeler management head scientific advisor professor of chemistry chemical biology ross clinical advisor university of colorado clinical advisor memorial sloan cancer center translational research advisor mass general cancer center pasi clinical advisor cancer institute nancy kohl translational research advisor independent consultant leadership team a james porter chief executive officer chief financial officer miller chief legal officer chief development turner chief medical officer ruth clinical operations josh chemistry officer benjamin lane technical operations lin corporate strategy portfolio management human resources henry drug discovery translational development business development strategy ease approvals | Nuvalent
Investor Presentation
January 2024
meet the significant experience in drug discovery development and company building board of directors scientific advisors independent independent hack bain capital life sciences flare therapeutics management anna protopapas independent james porter professor of chemistry chemical biology independent wheeler management head scientific advisor professor of chemistry chemical biology ross clinical advisor university of colorado clinical advisor memorial sloan cancer center translational research advisor mass general cancer center pasi clinical advisor cancer institute nancy kohl translational research advisor independent consultant leadership team james porter chief executive officer chief financial officer miller chief legal officer chief development turner chief medical officer officer me ruth clinical operations josh chemistry benjamin lane technical operations lin corporate strategy portfolio management human resources henry drug discovery translational development business development strategy or approvals meek lee | Nuvalent
Investor Presentation
January 2024
meet the significant experience in drug discovery development and company building board of directors scientific advisors independent independent hack bain capital life sciences flare therapeutics management anna protopapas independent james porter professor of chemistry chemical biology independent wheeler management head scientific advisor professor of chemistry chemical biology ross clinical advisor university of colorado clinical advisor memorial sloan cancer center translational research advisor mass general cancer center pasi clinical advisor cancer institute nancy kohl translational research advisor independent consultant leadership team james porter chief executive officer chief financial officer miller chief legal officer chief development turner chief medical officer officer me ruth clinical operations josh chemistry benjamin lane technical operations lin corporate strategy portfolio management human resources henry drug discovery translational development business development strategy prior approvals a a rea tablets | Nuvalent
Investor Presentation
November 2023
the team a | Nuvalent
Related slides by other companies
Theravance Biopharma
Results
February 2023
a session | Theravance Biopharma
Theravance Biopharma
Investor Conference
April 2023
a session | Theravance Biopharma
Cano Health
Investor Presentation
May 2023
strengthening our team to ensure the right people with the right are in the right roles | Cano Health
Walkme
Investor Day
May 2022
agenda | Walkme
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io